Patent ID: 7833721

Claim:
A method for diagnosing whether a human subject is likely to have inflammatory bowel disease (IBD), comprising: (a) contacting a mRNA-derived nucleic acid sample obtained from a human subject suspected of having IBD under hybridizing conditions with at least six 5 nucleotide probes, wherein a first nucleotide probe consists of 15 or more contiguous nucleotides of SEQ ID NO:3 (BLCAP) or a full complement thereof, a second nucleotide probe consists of 15 or more contiguous nucleotides of SEQ ID NO:5 (UBE2G1) or a full complement thereof, a third nucleotide probe consists of 15 or more contiguous nucleotides of SEQ ID NO:6 (CALM3) or a full complement thereof, a fourth nucleotide probe consists of 15 or more contiguous nucleotides of SEQ ID NO:13 (NONO) or a full complement thereof, and a fifth nucleotide probe and a sixth nucleotide probe consist of 15 or more contiguous nucleotides of a nucleic acid selected from the group consisting of: (i) SEQ ID NO:1 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof; (ii) SEQ ID NO:2 (RAP1A) and SEQ ID NO:7 (GPX1) or full complements thereof; (iii) SEQ ID NO:1 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof; and (iv) SEQ ID NO:2 (RAP1A) and SEQ ID NO:8 (GPX1) or full complements thereof; (b) detecting formation of hybridization complexes between the nucleotide probes and the nucleic acid targets in the nucleic acid sample, wherein the hybridization complexes provide a measure of gene expression of the nucleic acid targets; and (c) diagnosing whether the human subject is likely to have IBD based on the measure of gene expression of the nucleic acid targets, wherein gene expression levels of the nucleic acid targets differentiate between IBD and normal.